Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00556764 · ClinicalTrials.gov registry record · Early Phase 1

Development of Cognitive Assessment Tools in Parkinson Disease

A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.

Completed
Registry status
Early Phase 1
Development phase
75
Enrollment target

NCT00556764 is a Early Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 75 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00556764, a Early Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.

COMPLETED
Registry status
Early Phase 1
Development phase
75 participants
Enrollment target

Study Summary

The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparisons to available standardized cognitive evaluation scales administered to the patients with Parkinson disease with and healthy control subjects. 3. To evaluate the reliability of the ANAM-PD battery of tests by comparing repeated administrations of the ANAM-PD battery on a sub-set of subjects with Parkinson disease and healthy controls. 4. To characterize cholinergic neurotransmission through imaging the vesicular acetylcholine transporter binding with 123Iodobenzovesamicol (IBVM) and SPECT in PD patients and healthy controls.

Interventions

  • DRUG [123I] IBVM and SPECT imaging
  • DRUG Subjects will undergo the 123-I IBVM imaging visit

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2007-07
Est. Completion 2011-03
Phase Early Phase 1

What the Registry Record Tells You About NCT00556764

The ClinicalTrials.gov registry entry for NCT00556764 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which [123I] IBVM and SPECT imaging is the first listed.

NCT00556764 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00556764 about?

NCT00556764 is a clinical study titled "Development of Cognitive Assessment Tools in Parkinson Disease". The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparison...

What is the current status of trial NCT00556764?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2007-07. Estimated completion is 2011-03.

What interventions are being tested in trial NCT00556764?

The interventions under investigation include: [123I] IBVM and SPECT imaging (DRUG), Subjects will undergo the 123-I IBVM imaging visit (DRUG).

Who is sponsoring clinical trial NCT00556764?

This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.